Navigation Links
FDA Clears Cymbalta to Treat Chronic Musculoskeletal Pain
Date:11/4/2010

SILVER SPRING, Md., Nov. 4, 2010 /PRNewswire-USNewswire/ -- The U.S. Food and Drug Administration today approved Cymbalta (duloxetine hydrochloride) to treat chronic musculoskeletal pain, including discomfort from osteoarthritis and chronic lower back pain. Cymbalta was first used to treat major depressive disorder in 2004.  

(Logo: http://photos.prnewswire.com/prnh/20090824/FDALOGO)

(Logo: http://www.newscom.com/cgi-bin/prnh/20090824/FDALOGO)

"Up to three quarters of the population experience chronic pain at some time in their lives," said Janet Woodcock, M.D., director of FDA's Center for Drug Evaluation and Research. "This approval means that many of those people now have another treatment option."

Since its initial approval, about 30 million patients in the United States have used Cymbalta. It was approved for the treatment of diabetic peripheral neuropathy in 2004; generalized anxiety disorder and maintenance treatment of major depression in 2007; and fibromyalgia in 2008.

More than 29,000 patients have used Cymbalta in clinical trials, and more than 600 patients were studied in the clinical trials involving osteoarthritis and chronic low back pain. The safety evaluation for Cymbalta included review of data from the clinical trials as well as post-marketing data from the previously approved patient populations.

The FDA assessed the efficacy of Cymbalta in chronic low back pain and osteoarthritis in four double-blind, placebo-controlled, randomized clinical trials. At the end of the study period, patients taking Cymbalta had a significantly greater pain reduction compared with placebo.

The most common side effects reported with Cymbalta include nausea, dry mouth, insomnia, drowsiness, constipation, fatigue, and dizziness. Other serious side effects include liver damage, allergic reactions such as hives, rashes and/or swelling of the face, pneumonia, depressed mood, suicide, suicidal thoughts and behavior.

While these serious side effects have been associated with the use of Cymbalta, they have occurred in less than 1% of treated patients. There are a finite number of drugs available for the treatment of chronic musculoskeletal pain, all of which are associated with rare, serious side effects. There are patients in whom none of the available treatments are effective.  

The recommended dose for Cymbalta is a 60 milligram capsule taken once daily without regard to meals. The capsule should be swallowed whole, and not chewed, crushed or opened; the contents should never be sprinkled on food or mixed with liquids.

Consumers and health care professionals are encouraged to report adverse events to the FDA's MedWatch program at 800-FDA-1088 or online at www.fda.gov/medwatch/how.htm.

Cymbalta is manufactured by Indianapolis-based Eli Lilly and Co.

For more information:

Approved Drugs: Questions and Answers

Media Inquiries: Shelly Burgess, 301-796-4651, shelly.burgess@fda.hhs.gov

Consumer Inquiries: 888-INFO-FDA

#


'/>"/>
SOURCE U.S. Food and Drug Administration
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. FDA Clears Software Upgrade for Fenwal Plasma-Collection System
2. FDA Clears AirStrip RPM for CRITICAL CARE & CARDIOLOGY Remote Patient Monitoring Solutions
3. FDA Clears Xlumenas NAVIX(TM) Access Device
4. FDA Clears Three Additional Antimicrobials for Use on TREK Sensititre(R) In Vitro Diagnostic (IVD) MIC Susceptibility Plates: Minocycline and Telavancin Used to Treat MRSA and Other Infections; and Tigecycline, Now Cleared for Streptococcus Pneumoni
5. FDA Clears the Fenwal Amicus(R) Separator System for Collecting Platelets in New Additive Solution
6. FDA Grants Cequent IND - Clears Way for First-Ever Clinical Trial of Orally Delivered RNAi Therapeutic: CEQ508, a tkRNAi Drug Candidate in Oncology
7. FDA Clears the First Rapid Test to Detect Bacteria in Pooled Platelets
8. U.S. Food and Drug Administration Clears Alcatel-Lucent Remote Patient Monitoring Solution for Sale in the United States
9. Private Investment Firm Czura Thornton Today Introduces Clearstone Central Laboratories as the Newest Member of the Czura Thornton Life Science Group
10. FDA Clears a Test for Ovarian Cancer
11. U.S. Food and Drug Administration Clears Way for Multi-Center Clinical Trial of IDEV Technologies SUPERA Peripheral Stent
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/25/2016)... India , May 25, 2016 ... Review, H1 2016"market research report that provides an ... with comparative analysis at various stages, therapeutics assessment ... of administration (RoA) and molecule type, along with ... It also reviews key players involved in the ...
(Date:5/24/2016)... , May 24, 2016  Diana Russell suffers ... her organs from the inside out.  This disease has ... dependent on her children and grandchildren to leave her ... wheelchair, Diana,s family cannot haul the wheelchair.  So if ... the car, and Diana is left to wait for ...
(Date:5/24/2016)... 2016 The innovator of ... , s first dual therapy stent, introduces catheters ... OrbusNeich, a global company specializing in the provision ... include products to treat peripheral artery disease. The JADE™ ... devices for lower limb and arteriovenous (AV) fistula intervention. ...
Breaking Medicine Technology:
(Date:5/25/2016)... Newark, NJ (PRWEB) , ... May 25, 2016 ... ... the Kids’ Oral Health Program (KOHP), a $500,000 two-year pilot initiative to improve ... includes funding to support professional development for health care providers and promote best ...
(Date:5/25/2016)... ... May 25, 2016 , ... New studies published today by ... across 15 states. The outcomes examined in these studies include recovery of physical ... satisfaction with medical care. , “The goal of the studies is to provide ...
(Date:5/25/2016)... (PRWEB) , ... May 25, 2016 , ... Cheryl Bowker ... has to bestow: the Dick McKenna Good Hands Legacy Award. McKenna ran one of ... others which continues to inspire all those who knew him. The award named for ...
(Date:5/25/2016)... ... May 25, 2016 , ... Casa Velas, an adults-only boutique hotel in ... to complement its new wellness suites . The two 1,350 sq. ft. suites ... of special services and insuite amenities, from a custom soap selection and in-suite exercise ...
(Date:5/25/2016)... ... 2016 , ... Laser Skin & Wellness Center is excited to ... of female aging. The Juliet™ procedure helps to reverse the effects ... laxity, itchiness and pain have reported real relief from these and other problems by ...
Breaking Medicine News(10 mins):